Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Sponsor

Sheba Medical Center (Other)

Overall Status

Withdrawn

CT.gov ID

NCT02115672

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in improving the response to imatinib in CML patients not achieving an optimal response with imatinib alone.

Condition or Disease	Intervention/Treatment	Phase
Chronic Myeloid Leukemia	Drug: BL-8040	Phase 1/Phase 2

Detailed Description

To improve cytogenetic and molecular response of CML patients receiving Imatinib, who have not achieved an optimal response according to European LeukemiaNet (ELN) definitions , or MR4 after 24 months with Imatinib. This will be achieved by addition of the CXCR4 antagonist BL-8040, mobilizing CML leukemia stem cells from their protective bone marrow niche and exposing them to Imatinib and BL-8040-mediated apoptosis.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib.

Study Start Date :

Nov 1, 2014

Anticipated Primary Completion Date :

Nov 1, 2016

Anticipated Study Completion Date :

Nov 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: BL-8040 Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).	Drug: BL-8040 BL-8040 will be added to imatinib to improve CML response.

Arm

Intervention/Treatment

Experimental: BL-8040

Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).

Drug: BL-8040

BL-8040 will be added to imatinib to improve CML response.

Outcome Measures

Primary Outcome Measures

To assess the safety and tolerability of BL-8040 in combination with Imatinib in CML patients [4 months]
The investigators will assess the safety of the BL-8040 by grading of toxicities according to standard Common Toxicity Criteria for Adverse Effects (CTCAE) criteria.

Secondary Outcome Measures

To assess the clinical efficacy of BL-8040 in combination with Imatinib [2 years]
The cytogenetic and molecular response will be assessed by standard FISH and PCR test according to established criteria.

Other Outcome Measures

To assess additional pharmacodynamic parameters relevant to CXCR4 inhibition [2 months]
The investigators will test CXCR4 receptor occupancy and expression and additional pharmacodynamic endpoints relevant to CXCR4 inhibition.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult men and women subjects aged 18 to 70, inclusive.
Confirmed diagnosis of chronic phase CML according to the WHO criteria (WHO 2008)
CML patients with sub-optimal response to Tyrosine Kinase Inhibitors, defined as "warning" in the ELN recommendations:

Following 3 months: BCR-ABL1 > 10%, and/or Ph+ 36-95% Following 6 months: BCR-ABL1 1-10%, and/or Ph + 1-35% Following 12 months: BCR-ABL1 0.1-1 % Following 24 months: Less than MR4

Clinical laboratory values should be as follows:

White blood cell count < 30 X 10*9/L Creatinine < 1.5 ULN

Women of childbearing potential and all men must agree to use approved form of contraception
Subject is able and willing to comply with the requirements of the protocol.
Subject is able to voluntarily provide written informed consent.

Exclusion Criteria:

CML patients not in chronic phase.
CML patients receiving Tyrosine Kinase Inhibitors other than Imatinib.
CML patients receiving Imatinib > 400 mg/day.
Patients not able to sign informed consent.
Known allergy or hypersensitivity to any of the test compounds or materials or contraindication to test product.
Low Performance Status (ECOG > 2).
Abnormal liver function tests:
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) 2 x upper limit of normal (ULN).
Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L), conjugated bilirubin > 0.8 mg/dL
Abnormal left ventricular ejection fraction, < 40 %.
Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to:
Subject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy
A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.
Women subjects who are pregnant or breastfeeding.